Targeted small-molecule inhibition of BRAFV600E faces seemingly insurmountable obstacles in the clinic, such as rapid emergence of drug resistance. A recent study illustrates the potential of an alternative therapeutic strategy via PROTAC-mediated degradation of the oncogenic BRAF.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Karoulia, Z., Gavathiotis, E. & Poulikakos, P. I. Nat. Rev. Cancer 17, 676–691 (2017).
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. Nature 464, 427–430 (2010).
Hatzivassiliou, G. et al. Nature 464, 431–435 (2010).
Bollag, G. et al. Nature 467, 596–599 (2010).
Posternak, G. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-020-0609-7 (2020).
Bondeson, D. P. et al. Nat. Chem. Biol. 11, 611–617 (2015).
Gao, H., Sun, X. & Rao, Y. ACS Med. Chem. Lett. 11, 237–240 (2020).
Neklesa, T. et al. J. Clin. Oncol. 37, 259–259 (2019).
Han, X.-R. et al. J. Med. Chem. 63, 4069–4080 (2020).
Chen, H., Chen, F., Pei, S. & Gou, S. Bioorg. Chem. 87, 191–199 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.Z. is a stockholder and consultant to BridGene Biosciences.
Rights and permissions
About this article
Cite this article
Feng, J.J., Zhang, C. A two-pronged attack. Nat Chem Biol 16, 1154–1155 (2020). https://doi.org/10.1038/s41589-020-0647-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41589-020-0647-1
